Summit Therapeutics Inc.
General ticker "SMMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $13.5B (TTM average)
Summit Therapeutics Inc. does not follow the US Stock Market performance with the rate: -6.1%.
Estimated limits based on current volatility of 3.4%: low 14.71$, high 15.73$
Factors to consider:
- Earnings expected soon, date: nan
- Total employees count: 265 (+66.7%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Need additional capital, Economic downturns and volatility, Failure to achieve profitability, Regulatory and compliance, Commercial success risk
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.73$, 22.07$]
- 2026-12-31 to 2027-12-31 estimated range: [6.39$, 16.98$]
Financial Metrics affecting the SMMT estimates:
- Positive: with PPE of -12.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.79 <= 2.37
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 87.71 > 81.92
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: -0.37 < Inventory ratio change, % of 0
Short-term SMMT quotes
Long-term SMMT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $14.84MM |
| Operating Expenses | $609.65MM | $226.00MM | $1,094.42MM |
| Operating Income | $-609.65MM | $-226.00MM | $-1,079.59MM |
| Non-Operating Income | $-5.28MM | $4.68MM | $0.00MM |
| Interest Expense | $16.46MM | $8.69MM | $0.00MM |
| R&D Expense | $455.27MM | $132.42MM | $537.67MM |
| Income(Loss) | $-614.93MM | $-221.31MM | $-1,079.59MM |
| Net Income(Loss)* | $-614.93MM | $-221.31MM | $-1,079.59MM |
| Stockholders Equity | $77.69MM | $388.75MM | $658.86MM |
| Assets | $202.95MM | $435.56MM | $751.18MM |
| Operating Cash Flow | $-60.74MM | $-113.56MM | $-239.67MM |
| Capital expenditure | $0.10MM | $0.11MM | $0.49MM |
| Investing Cash Flow | $-465.14MM | $-164.09MM | $-129.37MM |
| Financing Cash Flow | $68.46MM | $304.63MM | $458.31MM |
| Earnings Per Share** | $-0.99 | $-0.31 | $-1.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.